France-based Bioptimus specializes in drug discovery, utilizing a large-language model (LLM) for the biotechnology sector. Bioptimus aims to adopt AI in understanding and utilizing multi-scale biological data, simplifying complex information to aid in discoveries.
Funding and financials
In February 2024, Bioptimus raised USD 35 million in seed funding led by Sofinnova Partners to integrate AI with biological sciences, aiming for scientific discoveries and personalized medical treatments. Moreover, the company planned to create models that predict and adapt to individual biological scenarios.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.